Lab celebration of Fabienne's appointment as the Director and CEO of QIMR Berghofer Medical Research Institute. @QIMRBerghofer @FabienneMackay
Wish you were here Yiqiao @jojo83603586. Hope to see you soon.
Renowned immunologist Professor @FabienneMackay has been appointed the eighth Director and CEO of #QIMRBerghofer. More via our website: https://t.co/q5UGbX2fUq
Lupus nephritis is a common and dangerous complication of lupus causing inflammation of the kidneys, and affects about 50% of people with lupus. Learn more about a new phase 3 study from GSK that shows positive clinical trial results for Benlysta® in LN: https://t.co/JLs288RVxb
More exciting #lupus treatment news! Today, @GSK announced positive results from a two-year study of Benlysta as a potential treatment specifically for lupus nephritis, which affects as many as 60% of adults and two-thirds of children with lupus.
Read more. #LupusResearch
Thanks to @nhmrc funding, Melbourne researchers will lead a major investigation to uncover why some people with age-related macular degeneration are at much greater risk of losing their sight. #AMD#EyeHealth#VisionResearch https://t.co/NOQDk9YZ2b
Thanks to @nhmrc funding, Melbourne researchers will lead a major investigation to uncover why some people with age-related macular degeneration are at much greater risk of losing their sight. #AMD#EyeHealth#VisionResearch https://t.co/NOQDk9YZ2b
LRA proudly announced at our 2019 Annual Scientific Conference two exceptional recipients of the 2019 Distinguished Innovator Award: Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD. Read More on how their study can potentially impact lupus treatments. 🔗https://t.co/kmTrEnpW32